The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Don Creighton
Advertisement
Articles by Don Creighton
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
The Drug Price Paradox: PBMs, Pharmacies, and the Path to Affordability
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
How mRNA and Protein-Based COVID-19 Vaccines Work
4
Updated Guideline Refines Approach to Migraine Prevention in Adults
5